Posted inClinical Updates Hematology-Oncology
Mivocabtagene Autoleucel CD19 CAR T-Cell Therapy in Stiff Person Syndrome: Efficacy, Safety, and Emerging Clinical Paradigm
This review synthesizes evidence from a pioneering phase 2 trial demonstrating that mivocabtagene autoleucel, a CD19 CAR T-cell therapy, achieves durable immunotherapy-free remissions with acceptable safety in antibody-positive stiff person syndrome.
